Brief: Windward Bio Launches With $200 Million Series A Financing
10/01/2025 14:09
Jan 10 (Reuters) - Windward Bio:
* WINDWARD BIO LAUNCHES WITH $200 MILLION SERIES A FINANCING
TO
DEVELOP PHASE 2-READY, LONG-ACTING ANTI-TSLP ANTIBODY WITH
BEST-IN-CLASS POTENTIAL IN ASTHMA AND COPD
* WINDWARD BIO: ORBIMED, NOVO HOLDINGS, AND BLUE OWL
HEALTHCARE
OPPORTUNITIES LEAD SERIES A FINANCING OF $200M
Source text: urn:newsml:reuters.com:*:nGNXbyhvDY
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study